Medication info

Telmisartan and Rosuvastatin Tablets 80/10 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pale orange oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Expired

MFDS item code 202101729 · Approved 2021.02.22

This product's status changed to Expired on 2026.02.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerotic progression; prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medication produces an additional blood pressure-lowering effect when administered with thiazide diuretics such as hydrochlorothiazide. The maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment when the dose is increased. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medication to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medications may be needed. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medication at 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product with the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerotic progression; prevention of cardiovascular disease

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is used for patients who require the combined use of Telmisartan and Rosuvastatin. Telmisartan is primarily helpful in the treatment of essential hypertension and reduction of cardiovascular disease risk. It particularly reduces the risk of myocardial infarction, stroke, and mortality due to cardiovascular diseases in patients with high-risk hypertension who cannot use ACE inhibitors. Rosuvastatin calcium is used as an adjunct to dietary therapy in patients with hypercholesterolemia and various dyslipidemias, lowering total cholesterol and LDL cholesterol levels to delay the progression of atherosclerosis. Additionally, it reduces the risk of stroke, myocardial infarction, and vascular revascularization in high-risk patients with cardiovascular disease risk factors. The combination of the two components is effective in the prevention and treatment of cardiovascular disease in patients with hypertension and dyslipidemia.

How to take

Adult dose

This medication is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan/rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medication produces an additional blood pressure-lowering effect when administered with thiazide diuretics such as hydrochlorothiazide. The maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment when the dose is increased. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When initiating treatment with this medication to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive medications may be needed. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medication and continue it throughout the treatment period. This medication may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medication at 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product with the same amounts of each active ingredient) for convenience.

Precautions

This medication should not be used during pregnancy. It can cause serious harm to the fetus and newborn, so if pregnancy is confirmed, the medication should be discontinued immediately. Patients who are allergic to this medication or have severe liver or kidney impairment should not take it. Special caution is warranted in cases of liver impairment or bile duct obstruction, as liver function may worsen. Elderly patients, those with hyperkalemia, and patients with liver impairment should use this medication cautiously, and they must regularly undergo liver function tests and blood potassium level checks during treatment. If symptoms such as muscle pain, muscle weakness, or muscle cramps occur, consult a doctor immediately. Caution is especially needed for those with a history of muscle-related diseases or who are taking other specific medications concurrently. As this medication lowers blood pressure, symptoms of hypotension may occur. If symptoms such as dizziness or fainting arise, rest immediately and seek medical attention if necessary. There may be interactions with other medications, so if you are taking other medicines, be sure to inform your doctor or pharmacist. Particular caution is needed when taken with diuretics, potassium-sparing diuretics, certain antibiotics, and immunosuppressants. This medication can affect liver and kidney function, so regular blood tests and physical examinations are required. Report any unusual symptoms to medical personnel immediately. Caution is advised when driving or operating machinery, as dizziness or drowsiness may occur. Children, pregnant women, and breastfeeding mothers should refrain from taking this medication, and women of childbearing potential should use appropriate contraceptive methods. In case of overdose, symptoms such as hypotension, dizziness, acute renal failure, etc. may occur, and emergency treatment should be sought immediately. This medication should be stored out of reach of children, and it is advisable not to transfer it to other containers.

Side effects

ALT elevation, AST elevation, elevated creatine phosphokinase (CPK) levels, dizziness, itching, dyspepsia, oral paresthesia, musculoskeletal stiffness, acne, nasopharyngitis, elevated potassium in the blood, glycosuria, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory tract infection, pharyngitis, sinusitis, urinary tract infection, cystitis, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, hypotension, orthostatic hypotension, shortness of breath, abdominal pain, diarrhea, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver function abnormality, liver impairment, increased sweating, rash, erythema, angioedema, drug-induced rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, elevated creatinine in the blood, elevated uric acid in the blood, increased liver enzymes, elevated CK in the blood, hemoglobin reduction, headache, facial spasms, sensory disturbances, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, reduced libido, facial edema, alopecia, conjunctivitis, ear noises, petechiae, hypoglycemia, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia gravis, headache, cough, palpitations, fatigue, nausea, lack of efficacy, numbness, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute kidney failure, oliguria, thrombocytopenia, elevated creatinine in the blood

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly closed container. The recommended storage temperature is between 1 and 30 degrees Celsius at room temperature. Proper storage will help maintain the efficacy and safety of the medication for a long time.

Appearance and packaging

Appearance

Pale orange oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.